Veteran Biotech Investor Talks of New Reality

By Steve Chapple Special to the U-T Saturday, June 23, 2012 La Jolla venture capitalist Kevin Kinsella: he’s happy, he’s not happy, he’s realistic. He’s happy because Avalon Ventures, which he founded in 1983, has just turned a $5.3 million…  Read More

AnaptysBio enters antibody partnership with Gilead

Mandy Jackson AnaptysBio is on a partnership roll: its agreement with Gilead Sciences, announcing on 1 May is its fourth new partnership in 2012 for the discovery of novel antibodies for partners. AnaptysBio, a private firm based in San Diego…  Read More

12 Investing and Business Gems from Avalon’s Kevin Kinsella

By Wade Rush Xconomy Current and former MIT students gathered at the Computer History Museum in Mountain View, CA, Tuesday night to hear one of San Diego’s most renowned venture investors, Avalon Ventures founder Kevin Kinsella, share insights from a long…  Read More

GHOST ship maker Juliet gets $9.67M

by Rodney Brown Mass High Tech Juliet Marine Systems Inc., Portsmouth, N.H., developer of the GHOST stealth littoral defense ship, has taken in $9.67 million in the company’s first institutional funding round, according to an SEC filing.

TechStars lands $24M more for start-up contests

Boston Herald By Donna Goodison  TechStars is now a more enriching experience for start-ups. The 14-week accelerator and seed-stage investment program will start offering each participating company an additional $100,000 in funding in the form of a convertible debt note.…  Read More

Entinostat May Overcome AI Resistance in Breast Cancer

Oncology Report Digital Network By: Susan London SAN FRANCISCO – Entinostat, a novel oral histone deacetylase inhibitor taken once weekly, may overcome resistance to hormonal therapy in breast cancer, the results of a randomized phase-II trial suggest.